A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | MicrobiomeTrials← Back to trialsNCT05708950
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
CompletedPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-03-03Est. Completion: 2025-10-16
Enrollment target: 40 participants Locations- UCLA Health (Santa Monica Cancer Care), Santa Monica, California, United States
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
- Sarah Cannon Research Institute at Florida Cancer Specialists, Sarasota, Florida, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Other microbiome trials you might be interested in
Endometrial Cancer
The objective of this clinical trial is to determine if a newly-designed and FDA-cleared vaginal speculum (the Bouquet S…
Englewood, United StatesCompleted Sep 30, 2026
Smoking Cessation
The primary objectives of this study are 1) to evaluate the longer-term impact of an adjunctive, low-cost financial ince…
Oklahoma City, United StatesCompleted Feb 8, 2022
Atypical Teratoid/Rhabdoid Tumor
Embryonal Tumor With Multilayered Rosettes
Ewing Sarcoma
Diffuse Intrinsic Pontine Glioma
Osteosarcoma
Neuroblastoma
DIPG Brain Tumor
The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (…
Birmingham, United StatesEst. completion May 2033